Abrogation of Vif function by peptide derived from the N-terminal region of the human immunodeficiency virus type 1 (HIV-1) protease (Q38334635)

2 September 2017

Abrogation of Vif function by peptide derived from the N-terminal region of the human immunodeficiency virus type 1 (HIV-1) protease (English)

1 reference

2 September 2017

Marina Hutoran

1

1 reference

2 September 2017

Elena Britan

2

1 reference

2 September 2017

Lea Baraz

3

1 reference

2 September 2017

Immanuel Blumenzweig

4

1 reference

2 September 2017

Michael Steinitz

5

1 reference

2 September 2017

Moshe Kotler

6

1 reference

2 September 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

2 September 2017

1 reference

2 September 2017

330

1 reference

2 September 2017

1

1 reference

2 September 2017

261-270

1 reference

The Vif protein of human immunodeficiency virus type 1 (HIV-1): enigmas and solutions

2 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

Human immunodeficiency virus type 1 Vif binds the viral protease by interaction with its N-terminal region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

Interaction of human immunodeficiency virus type 1 Vif with Gag and Gag-Pol precursors: co-encapsidation and interference with viral protease-mediated Gag processing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

HIV-1 Vif-derived peptide inhibits drug-resistant HIV proteases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

The Vif Protein of HIV Triggers Degradation of the Human Antiretroviral DNA Deaminase APOBEC3G

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

HIV with multiple gene deletions as a live attenuated vaccine for AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

A molecular clone of HTLV-III with biological activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

The sor gene of HIV-1 is required for efficient virus transmission in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

DNA deamination mediates innate immunity to retroviral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

The tyrosine kinase Hck is an inhibitor of HIV-1 replication counteracted by the viral vif protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

Intravirion processing of the human immunodeficiency virus type 1 Vif protein by the viral protease may be correlated with Vif function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

Cells surviving infection by human immunodeficiency virus type 1: vif or vpu mutants produce non-infectious or markedly less cytopathic viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

Synthetic peptides as substrates and inhibitors of a retroviral protease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

A new HTLV-III/LAV protein encoded by a gene found in cytopathic retroviruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

Human immunodeficiency virus 1 protease expressed in Escherichia coli behaves as a dimeric aspartic protease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

Role of Vif in stability of the human immunodeficiency virus type 1 core

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

A structural model for the retroviral proteases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

Peptide inhibitors of HIV-1 protease and viral infection of peripheral blood lymphocytes based on HIV-1 Vif.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

Complete nucleotide sequence of the AIDS virus, HTLV-III

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

The regulation of primate immunodeficiency virus infectivity by Vif is cell species restricted: a role for Vif in determining virus host range and cross-species transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

Evidence for a newly discovered cellular anti-HIV-1 phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

HIV-1 Vif Blocks the Antiviral Activity of APOBEC3G by Impairing Both Its Translation and Intracellular Stability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

The HIV 'A' (sor) gene product is essential for virus infectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

Molecular cloning of an apolipoprotein B messenger RNA editing protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

Phosphorylation of Vif and its role in HIV-1 replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

Identification of a host protein essential for assembly of immature HIV-1 capsids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

Replication and pathogenicity of human immunodeficiency virus type 1 accessory gene mutants in SCID-hu mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

7 January 2021

Human immunodeficiency virus type 1 Vif- mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

7 January 2021

Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

7 January 2021

Activity of avian retroviral protease expressed in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

7 January 2021

Expression and Characterization of Genetically Linked Homo- and Hetero-Dimers of Hiv Proteinase

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

7 January 2021

Mutational analysis of the human immunodeficiency virus type 1 Vif protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

7 January 2021

Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.029

7 January 2021

10.1016/J.VIROL.2004.09.029

Identifiers

DOI

1 reference

2 September 2017

1 reference